Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates

Earnings Call Insights: Coherus Oncology, Inc. (CHRS) Q4 2025

MANAGEMENT VIEW

* Dennis Lanfear, Chairman, President & CEO, stated, “This was a year in which we completed our strategic transformation to an innovative oncology company focused on overcoming immune resistance in cancer.” He highlighted the acquisition of Surface Oncology, the divestiture of the biosimilar franchise, and significant balance sheet improvement, including a reduction of $480 million in secured and convertible debt by over 90% to $38.8 million. Lanfear emphasized the launch and strong growth of LOQTORZI, describing it as “a commercial asset with growing sales in a rare disease space with no FDA-approved competing products on the horizon.”
* Lanfear provided the outlook that LOQTORZI is expected to reach $175 million in annualized revenues by 2028, corresponding to about 70% market share of a $250 million addressable market. He outlined milestones where, at about $15–16 million in quarterly sales, the commercial effort pays for itself, and at $30–35 million per quarter, the core burn is covered by revenues, expected in 2026 and 2027, respectively.
* Bryan McMichael, Chief Financial Officer, reported, “over 2024 and 2025, we decreased the principal balance of our term and convertible debt by over 90% from a high of $480 million to $38.8 million at year-end 2025.” McMichael also explained, “SG&A expenses from continuing operations decreased to $23.6 million, down from $29.6 million in Q4 last year.”
* Sameer Goregaoker, Chief Commercial Officer, announced, “LOQTORZI net revenue grew to $40.8 million for full year 2025, versus $19.1 million in 2024, representing 113% growth year-over-year.” Goregaoker added, “For Q4, net revenue was $12.4 million and 11% growth over Q3.”

OUTLOOK

* Management expects “average quarter-over-quarter demand growth of 10% to 15%” for LOQTORZI and aims to provide full year 2026 revenue guidance on the next earnings call in August.
* Lanfear commented, “Given the recent raise in our financial plans, we believe we are certainly sufficiently funded through key to day layouts in '26 and on into 2027.”
* Goregaoker reiterated the focus on achieving a dominant share in the NPC market, with peak share in 2028.

FINANCIAL RESULTS

* LOQTORZI net revenue for full year 2025 was $40.8 million, compared to $19.1 million in 2024. Q4 net revenue reached $12.4 million, reflecting 11% growth over Q3.
* SG&A expenses from continuing operations were $23.6 million for Q4, a decrease from $29.6 million in the prior year’s quarter. R&D expenses from continuing operations for Q4 were $31 million, compared to $20.8 million in Q4 2024.
* Cash equivalents and investments stood at $172.1 million at year-end, with recently raised capital including a $50 million follow-on offering.
* Reduction in legacy liabilities associated with divested businesses was significant, with accrued rebates, fees, and reserves at $30 million as of year-end, less than half the previous quarter’s $67 million.

Q&A

* Jay Olson, Oppenheimer, asked about new versus repeat patients for LOQTORZI and expected shifts in 2026. Sameer Goregaoker responded, “approximately 25% of our business came from new patients, and the rest came from continuing patients. I think that mix will shift slightly more towards new patients because we have a lot of opportunity to grow in the new patients.”
* Olson also inquired about promotional sensitivity and commercial investments. Goregaoker stated, “LOQTORZI is extremely promotion sensitive...when we do promote LOQTORZI to a physician, when we present the efficacy data, almost always we get complete buy-in.” He described a recent 15% expansion of the live sales force and the addition of inside sales representatives and a VA-targeted contract sales force.
* Michael Nedelcovych, TD Cowen, asked about casdozokitug trial tracking and planned data disclosures for tagmokitug. Rosh Dias, Chief Medical Officer, replied, “these are ongoing trials...we will report them when they are mature,” and outlined that data will be released at congresses or through corporate disclosure as available.
* Colleen Hanley, Baird, focused on data maturation timelines and competitive dynamics for CCR8. Dias discussed expectations for response rates and highlighted durability and overall clinical benefit as key measures. Theresa Lavallee, Chief Development Officer, commented on the competitive landscape, noting, “we expect to see the bookends of more data disclosures...we may see other programs being parked because of molecule issues.”
* Lut Ming Cheng, JPMorgan, asked about development priorities for the prostate cancer combo. Lavallee indicated, “all the studies are executable...given the prevalence and the need in CRPC, I mean, those studies should enroll relatively quickly.”
* Douglas Tsao, H.C. Wainwright, questioned cash flow breakeven and R&D spend strategy. Lanfear detailed, “the commercial spend includes the commercial team itself...probably $15 million, $16-ish million a quarter,” and clarified, “those [R&D spends] we view in a separate bucket...we’ve shown ourselves to be very judicious and thoughtful with our spends.”

SENTIMENT ANALYSIS

* Analysts’ tone was constructive but pressed for details on growth drivers, data timelines, and commercial execution. Questions highlighted interest in patient mix, promotional leverage, competitive landscape, and trial readouts.
* Management maintained a confident and proactive tone in both prepared remarks and Q&A, emphasizing progress, strategic investments, and financial discipline. Lanfear used phrases such as “we believe we are certainly sufficiently funded” and “we have a commercial asset with growing sales.”
* Compared to the previous quarter, management’s tone remains confident but with greater specificity regarding commercial milestones, funding sufficiency, and market share targets. Analyst sentiment showed sustained interest but increased focus on competitive differentiation, data disclosure, and operational execution.

QUARTER-OVER-QUARTER COMPARISON

* Guidance language evolved to include explicit revenue milestones for LOQTORZI, with management now targeting $175 million annualized revenue by 2028, compared to the previous quarter’s $150–200 million range.
* Strategic focus shifted from establishing foundational commercial infrastructure to expanding field force, enhancing CRM, and targeting specific market segments like VA hospitals.
* Financial discipline remains a recurring theme, with further headcount reductions and continued OpEx control highlighted.
* Analyst questions in the current quarter centered more on commercialization metrics, competitive positioning, and trial data release strategies compared to the prior quarter, which had a greater focus on pipeline mechanisms and development prioritization.
* Management’s confidence appears strengthened by recent revenue growth and debt reduction, while analysts are increasingly focused on timing and magnitude of commercial inflection points and competitive advances.

RISKS AND CONCERNS

* Management cited the competitive landscape in the Treg field, with Lanfear stating, “Treg field is increasingly competitive with some expected data readouts by other parties this year.”
* The company’s ability to convert new patients and expand in the community segment remains a challenge, as noted by Goregaoker: “community physicians manage multiple tumor types...NPC being rare is not always top of mind.”
* Analyst concerns centered on data maturation timelines, trial accrual rates, and the impact of competitor programs on development strategy.
* The company is mitigating financial risk by leveraging LOQTORZI revenues and securing partnerships that may offset pivotal trial costs.

FINAL TAKEAWAY

Over the past year, Coherus Oncology has completed a strategic pivot to focus on innovative oncology, divested its biosimilar business, reduced debt by more than 90%, and achieved substantial LOQTORZI sales growth. The company now targets $175 million in annualized LOQTORZI revenue by 2028, underpinned by continued expansion in the rare NPC market and enhanced commercial capabilities. Management emphasizes that LOQTORZI’s commercial progress will fund ongoing pipeline development, while multiple clinical data readouts and partnership opportunities are expected to support further value creation in the coming quarters.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/chrs/earnings/transcripts]

MORE ON COHERUS BIOSCIENCES

* Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4880266-coherus-oncology-inc-chrs-q4-2025-earnings-call-transcript]
* Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 [https://seekingalpha.com/article/4872703-coherus-downgrade-hold-on-potential-advancement-of-anti-ccr8-chs-114]
* Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript [https://seekingalpha.com/article/4859363-coherus-oncology-inc-chrs-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript]
* Coherus BioSciences Q4 2025 Earnings Preview [https://seekingalpha.com/news/4561989-coherus-biosciences-q4-2025-earnings-preview]
* Coherus Oncology prices stock offering to raise $50.1M [https://seekingalpha.com/news/4551720-coherus-oncology-prices-stock-offering-to-raise-501m]